Advertisement

Vincristine Local Delivery for Renal Artery Denervation

  • Konstantinos Toutouzas
  • Andreas Synetos
  • Christodoulos Stefanadis
Chapter

Abstract

The contribution of renal sympathetic nerve activity to the development and progression of resistant hypertension, has been convincingly demonstrated in both preclinical and human experiments. Preclinical experiments in hypertension models of hypertension [5, 6, 14], have successfully used renal denervation as both an experimental tool and a therapeutic strategy, but even earlier, in the absence of appropriate drugs to pharmacologically reduce blood pressure in severely hypertensive patients, therapeutic splanchnicectomy and even radical surgical sympathectomy were used since the 1930s. These surgical techniques have been abandoned due to their severe side effects. Recent studies have further investigated the close relationship between kidneys and brain, and gave light to some important parameters of this transaction. Low frequency stimulation of the sympathetic system resulted in renin excretion only, intermediate frequency stimulation results on decreased urinary sodium excretion and high frequency stimulation, results on direct renal artery vasoconstriction, decrease in renal blood flow and decrease glomerular filtration rate [2, 5, 10].

Keywords

Renal Artery Resistant Hypertension Local Delivery Office Blood Pressure Renal Denervation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Arndt C, Tefft M, Gehan E, Anderson J, Jenson M, Link M, Donaldson S, Breneman J, Wiener E, Webber B, Maurer H. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. J Pediatr Hematol Oncol. 1997;19(2):124–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Barajas L, Muller J. The innervation of the juxtaglomerular apparatus and surrounding tubules: a quantitative analysis by serial section electron microscopy. J Ultrastruct Res. 1973;43(1):107–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Carbone PP, Bono V, Frei 3rd E, Brindley CO. Clinical studies with vincristine. Blood. 1963;21:640–7.PubMedGoogle Scholar
  4. 4.
    Consigny PM, Davalian D, Donn R, Hu J, Rieser M, Stolarik D. Chemical renal denervation in the rat. Cardiovasc Intervent Radiol. 2013;37(1):218–23.PubMedCrossRefGoogle Scholar
  5. 5.
    DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension. 2004;43(2):147–50.PubMedCrossRefGoogle Scholar
  6. 6.
    Doumas M, Papademetriou V, Douma S, Faselis C, Tsioufis K, Gkaliagkousi E, Petidis K, Zamboulis C. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens. 2010;2011:318549.Google Scholar
  7. 7.
    Earl HM, Connolly S, Latoufis C, Eagle K, Ash CM, Fowler C, Souhami RL. Long-term neurotoxicity of chemotherapy in adolescents and young adults treated for bone and soft tissue sarcomas. Sarcoma. 1998;2:97–105.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, Li L, McCammack KC, Hall SD, Renbarger JL. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56(3):361–7.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2011;9756:1903–9.Google Scholar
  10. 10.
    Gewirtz JR, Bisognano JD. Catheter-based renal sympathetic denervation: a targeted approach to resistant hypertension. Cardiol J. 2011;1:97–102.Google Scholar
  11. 11.
    Holland JF, Scharlau C, Gailani S, Krant MJ, Olson KB, Horton J, Shnider BI, Lynch JJ, Owens A, Carbone PP, Colsky J, Grob D, Miller SP, Hall TC. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res. 1973;33(6):1258–64.PubMedGoogle Scholar
  12. 12.
    Ja'afer FM, Hamdan FB, Mohammed FH. Vincristine-induced neuropathy in rat: electrophysiological and histological study. Exp Brain Res. 2006;173(2):334–45.PubMedCrossRefGoogle Scholar
  13. 13.
    Kaltenbach B, Id D, Franke JC, Sievert H, Hennersdorf M, Maier J, Bertog SC. Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol. 2012;60(25):2694–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Kato T, Kassab S, Wilkins Jr FC, Kirchner KA, Granger JP. Decreased sensitivity to renal interstitial hydrostatic pressure in Dahl salt-sensitive rats. Hypertension. 1994;23(6 Pt 2):1082–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;9671:1275–81.CrossRefGoogle Scholar
  16. 16.
    LeQuesne. Neuropathy due to drugs; diseases of the peripheral nervous system. Peripheral neuropathy. 2nd ed. Philadelphia: WB Saunders Co; 1984. p. 2173–4.Google Scholar
  17. 17.
    Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. Eur Interv. 2012;​8(1):57–61.Google Scholar
  18. 18.
    Manning PT, Powers CW, Schmidt RE, Johnson Jr EM. Guanethidine-induced destruction of peripheral sympathetic neurons occurs by an immune-mediated mechanism. J Neurosci. 1983;3(4):714–24.PubMedGoogle Scholar
  19. 19.
    Mantadakis E, Amoiridis G, Kondi A, Kalmanti M. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J Pediatr Hematol Oncol. 2007;29(2):130.PubMedCrossRefGoogle Scholar
  20. 20.
  21. 21.
    Moore AS, Norris R, Price G, Nguyen T, Ni M, George R, van Breda K, Duley J, Charles B, Pinkerton RV. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health.Google Scholar
  22. 22.
    Pal PK. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol. 1999;39(6):323–30.PubMedGoogle Scholar
  23. 23.
    Rosenthal S, Kaufman S. Vincristine neurotoxicity. Ann Intern Med. 1974;80(6):733–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Stefanadis C. Renal denervation in resistant hypertension: radiofrequency ablation and chemical denervation. Hellenic J Cardiol. 2011;52(6):481–2.PubMedGoogle Scholar
  25. 25.
    Stefanadis C, Synetos A, Toutouzas K, Tsioufis C, Drakopoulou M, Tsiamis E, Agrogiannis G, Patsouris E, Tousoulis D. Barodenervation of the sympathetic nervous system of the renal artery. A new concept. Int J Cardiol. 2013;168(4):4443–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Stefanadis C, Synetos A, Toutouzas K, Tsioufis C, Drakopoulou M, Tsiamis E, Agrogiannis G, Patsouris E, Tousoulis D. New double balloon delivery catheter for chemical denervation of the renal artery with vincristine. Int J Cardiol. 2013;168(4):4346–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Stefanadis C, Toutouzas K, Synetos A, Tsioufis C, Karanasos A, Agrogiannis G, Stefanis L, Patsouris E, Tousoulis D. Chemical denervation of the renal artery by vincristine in swine. A new catheter based technique. Int J Cardiol. 2013;167(2):421–5.Google Scholar
  28. 28.
    Stefanadis C, Toutouzas K, Synetos A, Tsioufis C, Karanasos A, Agrogiannis G, Stefanis L, Patsouris E, Tousoulis D. Effectiveness of the denervation of the renal sympathetic nervous system by vincristine, by a constant flow rate delivery catheter. Int J Cardiol Subm. 2014.Google Scholar
  29. 29.
    Stefanadis C, Toutouzas K, Vlachopoulos C, Tsioufis C, Synetos A, Pietri P, Tousoulis D, Tsiamis E. Chemical denervation of the renal artery with vincristine for the treatment of resistant arterial hypertension: first-in-man application. Hellenic J Cardiol. 2013;54(4):318–21.PubMedGoogle Scholar
  30. 30.
    Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005;64(6):1076–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  • Konstantinos Toutouzas
    • 1
  • Andreas Synetos
    • 1
  • Christodoulos Stefanadis
    • 1
  1. 1.First Department of CardiologyAthens Medical School, Hippokration HospitalAthensGreece

Personalised recommendations